| Status: Recommended with restrictions | |||
Bevacizumab (Avastin®) is recommended as an option for restricted use within NHS Wales for use in combination with paclitaxel and cisplatin for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. Bevacizumab (Avastin®) is not recommended for use within NHS Wales for use in combination with paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent to or lower than the PAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | bevacizumab (Avastin®) | ||
| Formulation | 25 mg/ml concentrate for solution for infusion | ||
| Reference number | 5044 | ||
| Indication | In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Resubmission | ||
| Status | Recommended with restrictions | ||
| Advice number | 1122 | ||
| NMG meeting date | 11/05/2022 | ||
| AWMSG meeting date | 15/06/2022 | ||
| Date of issue | 17/06/2022 | ||
| Commercial arrangement | PAS | ||